Previous 10 | Next 10 |
LAUSANNE, Switzerland, March 04, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will provide oral presentations addressing the progress of four...
LAUSANNE, Switzerland, Feb. 07, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced two new appointments to its Executive Committee to accelerate the advanc...
Fortress Biotech (NASDAQ: FBIO ) +56% on Caelum deal with Alexion. More news on: Fortress Biotech, Inc., Prana Biotechnology Ltd, VistaGen Therapeutics, Inc., Stocks on the move, , Read more ...
To what should be absolutely no human being's surprise, another amyloid-antibody trial has failed. Roche ([[RHHBY]]) announced today that the Phase III work (two 750-patient trials) on crenezumab after an interim analysis showed a strong chance of futility. The company is still going on with...
Gainers: Co-Diagnostics (NASDAQ: CODX ) +114% . China SXT Pharmaceuticals (NASDAQ: SXTC ) +72% . Foresight Autonomous Holdings (NASDAQ: FRSX ) +31% . Horizon Global (NYSE: HZN ) +26% . BIO-key International (NASDAQ: BKYI ) +23% . Eyenovia (NASDAQ: EYEN ) +21% . Dunxin...
AC Immune SA (NASDAQ: ACIU ) -50% after discontinuing Phase III CREAD 1 and 2 studies of Crenezumab. More news on: AC Immune SA, Tupperware Brands Corporation, Trevena, Inc., Stocks on the move, , Read more ...
Roche ( OTCQX:RHHBY ) unit Genentech has decided to terminate its Phase 3 clinical trials, CREAD 1 and CREAD 2, evaluating crenezumab in people with early sporadic Alzheimer's disease (AD) after an interim analysis by the Independent Data Monitoring Committee showed that the studies were u...
Decision follows Independent Data Monitoring Committee analysis The Alzheimer’s Prevention Initiative (API) study of crenezumab in familial Alzheimer’s disease continues The Phase II anti-tau TAURIEL trial led by Roche in partnership with AC Immune continues ...
Recently, Eli Lilly ( LLY ) announced that it had formed a partnership deal for $2 billion to get its hands on an experimental drug for treatment of Alzheimer's disease. This deal marks for a major push for the company to develop a treatment for this neurological disease where treatment op...
2018 YTD Chart: +38.68% The benchmark S&P 500 index continues into negative territory for 2018 with over 5% declines this past week. The Momentum Gauges The Momentum Gauge signals continue to maintain higher levels of negative momentum than positive momentum since week 39 (last we...
News, Short Squeeze, Breakout and More Instantly...
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is fully funded and conducted by development partner ...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...